- Home
- MGIC vs LYEL Comparison
MGIC vs LYEL Comparison
Compare MGIC & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- LYEL
- Stock Information
- Founded
- MGIC 1983
- LYEL 2018
- Country
- MGIC Israel
- LYEL United States
- Employees
- MGIC N/A
- LYEL N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- LYEL Health Care
- Exchange
- MGIC Nasdaq
- LYEL Nasdaq
- Market Cap
- MGIC 788.0M
- LYEL 207.7M
- IPO Year
- MGIC 1991
- LYEL 2021
- Fundamental
- Price
- MGIC $21.34
- LYEL $9.51
- Analyst Decision
- MGIC Buy
- LYEL Sell
- Analyst Count
- MGIC 2
- LYEL 2
- Target Price
- MGIC $16.00
- LYEL $15.00
- AVG Volume (30 Days)
- MGIC 76.1K
- LYEL 177.3K
- Earning Date
- MGIC 08-13-2025
- LYEL 08-06-2025
- Dividend Yield
- MGIC 2.77%
- LYEL N/A
- EPS Growth
- MGIC 1.33
- LYEL N/A
- EPS
- MGIC 0.76
- LYEL N/A
- Revenue
- MGIC $569,136,000.00
- LYEL $65,000.00
- Revenue This Year
- MGIC $7.53
- LYEL N/A
- Revenue Next Year
- MGIC $8.96
- LYEL N/A
- P/E Ratio
- MGIC $27.61
- LYEL N/A
- Revenue Growth
- MGIC 6.37
- LYEL N/A
- 52 Week Low
- MGIC $9.64
- LYEL $7.65
- 52 Week High
- MGIC $21.98
- LYEL $38.40
- Technical
- Relative Strength Index (RSI)
- MGIC 80.60
- LYEL 49.76
- Support Level
- MGIC $20.17
- LYEL $9.11
- Resistance Level
- MGIC $21.98
- LYEL $9.84
- Average True Range (ATR)
- MGIC 0.52
- LYEL 0.63
- MACD
- MGIC 0.29
- LYEL -0.03
- Stochastic Oscillator
- MGIC 88.01
- LYEL 46.73
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.